Low LDH May Predict Second-Line Bevacizumab CRC ResponseLow LDH May Predict Second-Line Bevacizumab CRC Response

The addition of bevacizumab to second-line chemotherapy in metastatic colorectal cancer could be targeted to patients with low lactate dehydrogenase (LDH) levels, say Italian scientists. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news